{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:42:39Z","timestamp":1772134959325,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41433-025-03734-0","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:52:12Z","timestamp":1742489532000},"page":"1797-1804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SIRE: Short interval in real life Does intensive anti-VEGF treatment in the first year predict subsequent treatment burden in exudative age-related macular degeneration?"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7767-1548","authenticated-orcid":false,"given":"B.","family":"Matagrin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Fenniri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Chirpaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Billant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Agard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Chudzinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Burillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"3734_CR1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017;124:1753\u201363.","journal-title":"Ophthalmology"},{"key":"3734_CR2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet Lond Engl. 2012;379:1728\u201338.","journal-title":"Lancet Lond Engl"},{"key":"3734_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. CATT Research Group; Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"3734_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular de- generation. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"3734_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"3734_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. JS Ophthalmology (IF: 12 08; Q1). 2014;121:193\u2013201.","journal-title":"JS Ophthalmology (IF: 12 08; Q1)"},{"key":"3734_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679\u201380.","journal-title":"Am J Ophthalmol"},{"key":"3734_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","volume":"100","author":"D Chin-Yee","year":"2016","unstructured":"Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age- related macular degeneration. Br J Ophthalmol. 2016;100:914\u20137.","journal-title":"Br J Ophthalmol"},{"key":"3734_CR9","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration. Retina. 2021;41:1911. Sep Published online 2021 Mar 22.","journal-title":"Retina"},{"key":"3734_CR10","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","volume":"120","author":"L Kodjikian","year":"2013","unstructured":"Kodjikian L, Souied EH, Mimoun G, Mauget-Fa\u00ffsse M, Behar-Cohen F, Decullier E, et al. GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013;120:2300\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2013.06.020. NovEpub 2013 Aug 2. PMID: 23916488.","journal-title":"Ophthalmology"},{"key":"3734_CR11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, ALTAIR Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age- Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"3734_CR12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"IVAN Study Investigators, Chakravarthy U, Harding SP, Rog- ers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neo- vascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"3734_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018;125:537\u201348.","journal-title":"Ophthalmology"},{"key":"3734_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"3734_CR15","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","volume":"30","author":"KB Freund","year":"2010","unstructured":"Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina Phila Pa. 2010;30:1333\u201349.","journal-title":"Retina Phila Pa"},{"key":"3734_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000535806","volume":"247","author":"P Leroux","year":"2024","unstructured":"Leroux P, Bouvarel H, Badri Y, Douma I, Pradat P, Dot C. Long Intervals between Intravitreal Injections Using a Treat-and-Extend Protocol in a Real-Life Context in AMD: The LIRE Study. Ophthalmologica. 2024;247:44\u201357.","journal-title":"Ophthalmologica"},{"key":"3734_CR17","doi-asserted-by":"publisher","first-page":"00006","DOI":"10.1016\/j.oret.2024.01.004","volume":"S2468-6530","author":"C Boudousq","year":"2024","unstructured":"Boudousq C, Nguyen V, Hunt A, Zarranz-Ventura J, Creuzot-Garcher C, Gabrielle PH. European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2024;S2468-6530:00006\u2013X. https:\/\/doi.org\/10.1016\/j.oret.2024.01.004.","journal-title":"Ophthalmol Retina"},{"key":"3734_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ophtha.2012.08.008","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Chen E, Mariani A, Major JC Jr, SAVE Study G. Super-dose anti-VEGF (SAVE) trial: 2.0mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013;120:349\u201354.","journal-title":"Ophthalmology"},{"key":"3734_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/OPTH.S125676","volume":"11","author":"K Spooner","year":"2017","unstructured":"Spooner K, Hong T, Wijeyakumar W, Chang AA. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clin Ophthalmol. 2017;11:161\u201377.","journal-title":"Clin Ophthalmol"},{"key":"3734_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.oret.2021.04.015","volume":"6","author":"L Kodjikian","year":"2022","unstructured":"Kodjikian L, Rezkallah A, Decullier E, Aulagner G, Huot L, Mathis T. GEFAL Study Group. Early Predictive Factors of Visual Loss at 1 Year in Neovascular Age-Related Macular Degeneration under Anti-Vascular Endothelial Growth Factor. Ophthalmol Retina. 2022;6:109\u201315.","journal-title":"Ophthalmol Retina"},{"key":"3734_CR21","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.xops.2022.100114","volume":"2","author":"CP Creuzot-Garcher","year":"2022","unstructured":"Creuzot-Garcher CP, Srour M, Baudin F, Daien V, Dot C, Delcourt C. Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018: The LANDSCAPE Study. Ophthalmol Sci. 2022;2:100114.","journal-title":"Ophthalmol Sci"},{"key":"3734_CR22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.oret.2019.11.004","volume":"4","author":"G Bontzos","year":"2020","unstructured":"Bontzos G, Bagheri S, Ioanidi L, Kabanarou S, Miller J, Vavvas DG. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2020;4:1138\u201345. https:\/\/doi.org\/10.1016\/j.oret.2019.11.004. DecEpub 2019 Nov 11. PMID: 31937473; PMCID: PMC7416963.","journal-title":"Ophthalmol Retina"},{"key":"3734_CR23","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S, Yoon YH, Eter N, Chen LJ, et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond). 2023;37:1758\u201365.","journal-title":"Eye (Lond)"},{"key":"3734_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0015-6","volume":"1","author":"E Dhrami-Gavazi","year":"2015","unstructured":"Dhrami-Gavazi E, Balaratnasingam C, Lee W, Freund KB. Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration. Int J Retina Vitreous. 2015;1:15. Published online 2015 Sep 3.","journal-title":"Int J Retina Vitreous"},{"key":"3734_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","volume":"159","author":"RB Bhisitkul","year":"2015","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915\u201324.e912.","journal-title":"Am J Ophthalmol"},{"key":"3734_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018;125:878\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.026. JunEpub 2018 Feb 21. PMID: 29477692.","journal-title":"Ophthalmology"},{"key":"3734_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"3734_CR28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Figueroa MS, Lin H, Viola F, Wong TY, et al. TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"3734_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023;141:834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"3734_CR30","doi-asserted-by":"publisher","first-page":"00063","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"S0140-6736","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. PULSAR Investigators. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;S0140-6736:00063\u20131. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","journal-title":"Lancet"},{"key":"3734_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.oret.2020.07.028","volume":"5","author":"DR Matsunaga","year":"2021","unstructured":"Matsunaga DR, Su D, Sioufi K, Obeid A, Wibbelsman T, Ho AC, et al. The Timing of Large Submacular Hemorrhage Secondary to Age-Related Macular Degeneration Relative to Anti-VEGF Therapy. Ophthalmol Retina. 2021;5:342\u20137. https:\/\/doi.org\/10.1016\/j.oret.2020.07.028.","journal-title":"Ophthalmol Retina"},{"key":"3734_CR32","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1167\/iovs.09-3582","volume":"51","author":"SS Lee","year":"2010","unstructured":"Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:2135\u20138. https:\/\/doi.org\/10.1167\/iovs.09-3582. AprEpub 2009 Dec 17. PMID: 20019364.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3734_CR33","doi-asserted-by":"publisher","first-page":"e0252006","DOI":"10.1371\/journal.pone.0252006","volume":"16","author":"Y Mun","year":"2021","unstructured":"Mun Y, Park KH, Park SJ, Woo SJ. Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes. PLoS One. 2021;16:e0252006 https:\/\/doi.org\/10.1371\/journal.pone.0252006. Jun 10PMID: 34111133; PMCID: PMC8191940.","journal-title":"PLoS One"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03734-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03734-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03734-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:23:52Z","timestamp":1748852632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03734-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3734"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03734-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4715591\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}